In the last decade, increasing antibiotic resistance (AMR) has been encountered among human and veterinary bacterial pathogens. The accelerating emergence and dissemination of antibiotic resistance in pathogenic bacteria makes more bacterial infections difficult to treat. A recently published article in the Lancet shows that 1.27 million deaths were directly attributable to antibiotic-resistant bacterial infections in 2019. Despite the AMR situation being so urgent, the number of newly approved antibiotics has been steadily decreasing over the past 50 years. To address the problem posed by AMR bacterial infections, novel antibiotics are desperately needed.
Antimicrobial peptides (AMPs) have been proven to have therapeutic effects against various diseases, and many of those AMPs have been approved and used in clinical treatment. Notably, most of the approved AMP drugs, such as vancomycin, daptomycin, and colistin, are used for the treatment of bacterial infections. This research topic aims to cover new discoveries of two types of important AMPs, nonribosomal peptides (NRPs) or ribosomally synthesized and post-translationally modified peptides (RiPPs), NRPs(or RiPPs)-derived products and NRPs(or RiPPs) mimics that have highly application potentials for controlling antibiotic-resistant bacterial infections.
This research topic welcomes studies focusing on but not limited to:
1) The discovery and development of novel (NRPs) or (RiPPs) by synthetic biology, semisynthetic and genome mining
2) Structure-activity relationship studies of novel NRPs or RiPPs;
3) Antibacterial mechanisms of novel NRPs or RiPPs;
4) Novel NRPs or RiPPs that act as sensitizers of bacteria to other antibiotics.
In the last decade, increasing antibiotic resistance (AMR) has been encountered among human and veterinary bacterial pathogens. The accelerating emergence and dissemination of antibiotic resistance in pathogenic bacteria makes more bacterial infections difficult to treat. A recently published article in the Lancet shows that 1.27 million deaths were directly attributable to antibiotic-resistant bacterial infections in 2019. Despite the AMR situation being so urgent, the number of newly approved antibiotics has been steadily decreasing over the past 50 years. To address the problem posed by AMR bacterial infections, novel antibiotics are desperately needed.
Antimicrobial peptides (AMPs) have been proven to have therapeutic effects against various diseases, and many of those AMPs have been approved and used in clinical treatment. Notably, most of the approved AMP drugs, such as vancomycin, daptomycin, and colistin, are used for the treatment of bacterial infections. This research topic aims to cover new discoveries of two types of important AMPs, nonribosomal peptides (NRPs) or ribosomally synthesized and post-translationally modified peptides (RiPPs), NRPs(or RiPPs)-derived products and NRPs(or RiPPs) mimics that have highly application potentials for controlling antibiotic-resistant bacterial infections.
This research topic welcomes studies focusing on but not limited to:
1) The discovery and development of novel (NRPs) or (RiPPs) by synthetic biology, semisynthetic and genome mining
2) Structure-activity relationship studies of novel NRPs or RiPPs;
3) Antibacterial mechanisms of novel NRPs or RiPPs;
4) Novel NRPs or RiPPs that act as sensitizers of bacteria to other antibiotics.
